|20 nM||30 nM||510 nM|
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||33.75 mL||168.74 mL||337.47 mL|
|0.5 mM||6.75 mL||33.75 mL||67.49 mL|
|1 mM||3.37 mL||16.87 mL||33.75 mL|
|5 mM||0.67 mL||3.37 mL||6.75 mL|
*The above data is based on the productmolecular weight 296.32. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
|Synonyms||SU5402, SU 5402|
Canertinib (CI-1033) is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (I…
Mubritinib (TAK 165) is a potent EGFR and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 µM, respectively. Mubritinib(TAK 165) also inhibits p…
PD158780 is a very potent inhibitor of EGFR with IC50 of 0.08 nM; pan-specific antagonist of ErbB receptor.
WZ8040 is a novel EGFR inhibitors that suppress the growth of EGFR-T790M-containing cell lines and inhibit EGFR phosphorylation.
CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor …
Pelitinib (EKB-569) is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity.
PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HE…